Pandemic 2009 H1N1 Influenza A Virus Carrying a Q136K Mutation in the Neuraminidase Gene Is Resistant to Zanamivir but Exhibits Reduced Fitness in the Guinea Pig Transmission Model

ABSTRACT Resistance of influenza A viruses to neuraminidase inhibitors can arise through mutations in the neuraminidase (NA) gene. We show here that a Q136K mutation in the NA of the 2009 pandemic H1N1 virus confers a high degree of resistance to zanamivir. Resistance is accompanied by reduced numbers of NA molecules in viral particles and reduced intrinsic enzymatic activity of mutant NA. Interestingly, the Q136K mutation strongly impairs viral fitness in the guinea pig transmission model.

[1]  V. Streltsov,et al.  In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir. , 2012, The Journal of antimicrobial chemotherapy.

[2]  J. Peiris,et al.  Comparable Fitness and Transmissibility between Oseltamivir-Resistant Pandemic 2009 and Seasonal H1N1 Influenza Viruses with the H275Y Neuraminidase Mutation , 2012, Journal of Virology.

[3]  C. Chappey,et al.  Safety, Tolerability, and Pharmacokinetics of Intravenous Oseltamivir: Single- and Multiple-Dose Phase I Studies with Healthy Volunteers , 2012, Antimicrobial Agents and Chemotherapy.

[4]  Maria Zambon,et al.  Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. , 2012, The Lancet. Infectious diseases.

[5]  Erhard van der Vries,et al.  Multidrug Resistant 2009 A/H1N1 Influenza Clinical Isolate with a Neuraminidase I223R Mutation Retains Its Virulence and Transmissibility in Ferrets , 2011, PLoS pathogens.

[6]  W. Furman,et al.  Severe H1N1‐associated acute respiratory failure in immunocompromised children , 2011, Pediatric blood & cancer.

[7]  C. Boucher,et al.  Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. , 2010, The New England journal of medicine.

[8]  G. Kochs,et al.  Oseltamivir-Resistant Variants of the 2009 Pandemic H1N1 Influenza A Virus Are Not Attenuated in the Guinea Pig and Ferret Transmission Models , 2010, Journal of Virology.

[9]  Ryo Takano,et al.  Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses , 2010, PLoS pathogens.

[10]  R. Webster,et al.  Oseltamivir–Resistant Pandemic H1N1/2009 Influenza Virus Possesses Lower Transmissibility and Fitness in Ferrets , 2010, PLoS pathogens.

[11]  G. Kobinger,et al.  Oseltamivir-Resistant Pandemic A/H1N1 Virus Is as Virulent as Its Wild-Type Counterpart in Mice and Ferrets , 2010, PLoS pathogens.

[12]  D. Baltimore,et al.  Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.

[13]  J. Chappell,et al.  Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Ha T. Nguyen,et al.  Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. , 2010, Antiviral research.

[15]  E. Tuomanen,et al.  Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. , 2010, The New England journal of medicine.

[16]  A. Moscona,et al.  Global transmission of oseltamivir-resistant influenza. , 2009, The New England journal of medicine.

[17]  C. Mar,et al.  Possible harms of oseltamivir—a call for urgent action , 2009, The Lancet.

[18]  A. Kelso,et al.  Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation , 2009, Journal of Virology.

[19]  A. Hurt,et al.  Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. , 2009, Antiviral research.

[20]  J. van de Kassteele,et al.  Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season , 2009, Emerging infectious diseases.

[21]  L. Brammer,et al.  Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. , 2009, JAMA.

[22]  A. Lackenby,et al.  Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007–08 , 2009, Emerging infectious diseases.

[23]  T. Mettenleiter,et al.  Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase. , 2009, Vaccine.

[24]  Arnold Martin,et al.  Processing of Genome 5′ Termini as a Strategy of Negative-Strand RNA Viruses to Avoid RIG-I-Dependent Interferon Induction , 2008, PloS one.

[25]  Erik De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature Reviews Drug Discovery.

[26]  Janet Daly,et al.  Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. , 2006, The Journal of antimicrobial chemotherapy.

[27]  R. Webster,et al.  Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility , 2005, Antimicrobial Agents and Chemotherapy.

[28]  H. Klenk,et al.  Overexpression of the α-2,6-Sialyltransferase in MDCK Cells Increases Influenza Virus Sensitivity to Neuraminidase Inhibitors , 2003, Journal of Virology.

[29]  F. Hayden,et al.  Evaluation of Neuraminidase Enzyme Assays Using Different Substrates To Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network , 2003, Journal of Clinical Microbiology.

[30]  J. Oxford,et al.  The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. , 2002, Antiviral research.

[31]  J. Oxford,et al.  Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. , 2002, Antiviral research.

[32]  R. Webster,et al.  Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en , 1997, Journal of virology.

[33]  P. Colman,et al.  The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor , 1992, Proteins.

[34]  I. Barr,et al.  Oseltamivir Resistance and the H274Y Neuraminidase Mutation in Seasonal, Pandemic and Highly Pathogenic Influenza Viruses , 2012, Drugs.

[35]  Guy Boivin,et al.  Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. , 2011, The Journal of infectious diseases.

[36]  Mark von Itzstein,et al.  The war against influenza: discovery and development of sialidase inhibitors. , 2007, Nature reviews. Drug discovery.

[37]  Alan Bye,et al.  Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers , 1999, Clinical pharmacokinetics.

[38]  I Mahmood,et al.  The Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I Protocols , 1999, Clinical pharmacokinetics.